The potential of AI in the optimization of diagnostic processes in healthcare (14:30 - 14:40)
Artificial intelligence promises to speed up and sharpen the diagnosis of prostate cancer, which today is demanding in terms of both time and human resources. Pavol Praženica, a physician and co-founder of the Medan platform, presented how a cloud solution helps radiologists and urologists with screening. The goal is to shorten the wait for results and limit unnecessary invasive procedures. Prostate cancer screening requires the involvement of general practitioners, urologists, radiologists, and pathologists, but the system is overloaded. Among men over 65, the incidence of the disease is up to 60 %, according to the speaker, yet many do not undergo preventive check-ups. In Slovakia, the path to early detection thus stretches to roughly 180 days, while the OECD country average is 45 to 70 days. The standard pathway starts with the general practitioner with a PSA test: at a value of <1 a follow-up is scheduled in 4 years, at 1–3 in 2 years, and at ≥3 the patient is referred to a urologist. With PSA density above 0,1, MRI is indicated, from which the radiologist assigns a PI‑RADS score. Categories 1–2 usually do not require intervention, but category 3 is a "gray zone" and often leads to biopsy, which may be unnecessary and carries risks, for example erectile dysfunction.Where the diagnostic process stalls
